/
Corporate Information We were originally incorporated in the State of Delaware in April 2003 as PharmacoFore, Inc. and, in January 2012, we changed our name from PharmacoFore, Inc. to Signature Therapeutics Inc. ( Signature ). In December 2015, Signature merged with and into Ensysce Biosciences, Inc. ( Former Ensysce ).
The business is unprofitable at the operating level (-202.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 2.8% YoY. Margins deteriorated 72.9pp alongside, both lines moving the wrong way.
ROIC dropped from -176.60% to -198.81%, capital efficiency is deteriorating. Negative free cash flow of -$8M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$5M
▼ -2.8% YoY
Net Income (TTM)
-$12M
▼ -27.4% YoY
Op. Margin
-251.40%
▼ -72.9pp YoY
ROIC
-354.99%
▼ -22.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -5.7% YoY
Op. Cash Flow (TTM)
-$10M
▼ -4.0% YoY
Net Debt
-$254K
Net Cash Position
Cash & Equiv.
$745K
5Y CAGR: +5.2%
Continue Research